A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin

NCT00441519 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2009-01-12

No results posted yet for this study

Summary

To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet

Conditions

  • Healthy

Interventions

DRUG

aspirin

DRUG

omeprazole

Sponsors & Collaborators

  • POZEN

    lead INDUSTRY

Principal Investigators

  • Judy Bryson, Pharm. D. · POZEN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00441519 on ClinicalTrials.gov